Aaron Cowen Suvretta Capital Management
Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MANE
Veradermics Inc
MANE
|
+$210M |
| 2 |
Capricor Therapeutics
CAPR
|
+$54.2M |
| 3 |
Vulcan Materials
VMC
|
+$53.4M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$46.6M |
| 5 |
Performance Food Group
PFGC
|
+$35.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Erasca
ERAS
|
+$131M |
| 2 |
Coca-Cola
KO
|
+$96.7M |
| 3 |
Microsoft
MSFT
|
+$64.7M |
| 4 |
ServiceNow
NOW
|
+$59.7M |
| 5 |
Salesforce
CRM
|
+$53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.36% |
| 2 | Technology | 6.7% |
| 3 | Consumer Discretionary | 5.89% |
| 4 | Financials | 4.13% |
| 5 | Consumer Staples | 3.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
W.W. Grainger
GWW
$61.8B
| $1.09M | 0.03% |
+1,000
| New | +$1.09M |
|
|
FTH
77
Faeth Therapeutics
FTH
$827M
| $1.09M | 0.03% |
+34,549
| New | +$690K |
|
78
Waters Corp
WAT
$40.4B
| $960K | 0.02% |
3,225
+75
| +2% | +$25.7K |
|
79
Vistra
VST
$45.7B
| $902K | 0.02% |
+6,000
| New | +$971K |
|
80
Ionis Pharmaceuticals
IONS
$9.93B
| $811K | 0.02% |
10,800
| – | – |
|
81
Agilent Technologies
A
$44.9B
| $569K | 0.01% |
4,990
| – | – |
|
82
ResMed
RMD
$33.4B
| $537K | 0.01% |
2,390
| – | – |
|
83
Spotify
SPOT
$110B
| $533K | 0.01% |
+1,100
| New | +$552K |
|
84
Veralto
VLTO
$24.1B
| $484K | 0.01% |
5,475
| – | – |
|
85
Roblox
RBLX
$27.4B
| $476K | 0.01% |
+8,420
| New | +$565K |
|
86
Sarepta Therapeutics
SRPT
$1.98B
| $389K | 0.01% |
17,888
| – | – |
|
87
Steris
STE
$23.2B
| $338K | 0.01% |
1,530
| – | – |
|
88
Viridian Therapeutics
VRDN
$2.75B
| $327K | 0.01% |
16,700
| – | – |
|
89
Zimmer Biomet
ZBH
$19.3B
| $295K | 0.01% |
3,260
| – | – |
|
90
PUT
ARK Genomic Revolution ETF
ARKG
$1.94B
| – | – |
-8,342,300
| Closed | -$242M |
|
91
Biogen
BIIB
$32B
| – | – |
-132,290
| Closed | -$23.3M |
|
92
Chipotle Mexican Grill
CMG
$46.7B
| – | – |
-686,300
| Closed | -$25.4M |
|
93
Charles River Laboratories
CRL
$14.1B
| – | – |
-1,010
| Closed | -$201K |
|
|
94
Salesforce
CRM
$171B
| – | – |
-199,900
| Closed | -$53M |
|
95
Dick's Sporting Goods
DKS
$16.4B
| – | – |
-114,300
| Closed | -$22.6M |
|
|
EXAS
96
DELISTED
Exact Sciences
EXAS
| – | – |
-94,100
| Closed | -$9.56M |
|
97
Goldman Sachs
GS
$303B
| – | – |
-24,108
| Closed | -$21.2M |
|
98
PUT
Hims & Hers Health
HIMS
$7.88B
| – | – |
-2,559,400
| Closed | -$83.1M |
|
99
Insmed
INSM
$27.5B
| – | – |
-109,313
| Closed | -$19M |
|
|
100
Coca-Cola
KO
$392B
| – | – |
-1,382,750
| Closed | -$96.7M |
|
Similar funds
Aaron Cowen's Q1 2026 Portfolio in Review
As of Q1 2026, Aaron Cowen held 108 positions worth $3.92B, down 20% from $4.88B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Aaron Cowen withdrew a net $852M in Q1 2026, closing 19 positions and reducing 16 holdings. Its most notable exit was Coca-Cola, an estimated $96.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 51% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Aaron Cowen opened a new position in Veradermics Inc worth $263M.
- Aaron Cowen's largest Q1 2026 buy was Veradermics Inc: 4,168,970 shares worth $263M.
- Aaron Cowen added most to Capricor Therapeutics in Q1 2026, an estimated $54.2M increase.
- Aaron Cowen's biggest Q1 2026 reduction was Erasca, cutting an estimated $131M.
- Aaron Cowen fully exited Coca-Cola in Q1 2026, selling an estimated $96.7M.
- Aaron Cowen's ten largest holdings make up 42% of its $3.92B portfolio in Q1 2026.
- Aaron Cowen opened 15 new positions and closed 19 in Q1 2026.
- Aaron Cowen's portfolio value fell 20% quarter-over-quarter to $3.92B.
Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.